Eli Lilly & Co. vs. SELLAS Life Sciences Group, Inc. Common Stock
LLY
Eli Lilly & Co.
$1255.40 +0.88%
VS SLSSELLAS Life Sciences Group, Inc. Common Stock
$15.46 +15.37%
SELLAS Life Sciences Group, Inc. Common Stock (SLS) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| LLY | SLS | |
|---|---|---|
| Market Cap | $1.12 trillion | $3.12 billion |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | SLS | |
|---|---|---|
| P/E Ratio | 42.14 | — |
| Price / Book | 33.03 | — |
| Price / Sales | 14.05 | — |
LLY and SLS split the valuation factors evenly.
Profitability
| LLY | SLS | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | — |
LLY and SLS split the profitability factors evenly.
Dividend
| LLY | SLS | |
|---|---|---|
| Dividend Yield | 0.55% | 6.22% |
| Payout Ratio | 23.23 | — |
SLS leads on 1 of 1 dividend factors.
Risk & Sentiment
| LLY | SLS | |
|---|---|---|
| Short Interest | 1.29% | 0.06% |
SLS leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SLS overview, SLS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.